SI-BONE's innovative approach fuels both EBITDA gains and increased revenue

On November 10, 2025, SI-BONE, Inc. (NASDAQ: SIBN) announced its third-quarter 2025 financial results, surpassing expectations with a positive adjusted EBITDA and an updated annual revenue outlook now ranging from $198 million to $200 million. The company, recognized worldwide for its sacropelvic disorder solutions, also revealed plans for a conference call to provide a detailed review of its latest performance.

.

Gross margin improved to 79.8% in the third quarter of 2025, an increase of 75 basis points from 79.1% in the same quarter last year, attributed to enhanced operational efficiency. Operating expenses climbed by 11.9% to $44.2 million, reflecting expanded commercial efforts for new product introductions and higher administrative spending. Despite these increases, the operating loss was reduced by 29.5% to $5.4 million, and net loss narrowed by 30.6% to $4.6 million, or $0.11 per diluted share, compared to $6.6 million, or $0.16 per share, a year earlier.

Adjusted EBITDA reached $2.3 million, a turnaround from a $0.2 million loss in the third quarter of 2024 .

As of September 30, 2025, SI-BONE’s cash balance stood at $145.7 million, unchanged from the prior quarter. The company raised its full-year 2025 outlook, now expecting revenue to grow by 18-20% to between $198 million and $200 million, while maintaining a gross margin near 79.5%. These projections highlight the company’s confidence in its market standing, with CEO David B. Robinson crediting the results to “the ongoing adoption of our minimally invasive solutions” and the company’s expanding international presence.

.

The updated outlook demonstrates SI-BONE’s ability to thrive in a challenging healthcare environment. Since introducing minimally invasive sacroiliac joint procedures in 2009, the company has enabled more than 4,900 physicians to perform over 135,000 surgeries. Industry analysts point out that SI-BONE’s emphasis on innovation and broadening the use of its technologies positions it well to further increase its share in the orthopedic market.

.

A live webcast and conference call to review the financial results will take place on November 10, 2025, at 4:30 p.m. Eastern Time. The event will be accessible for at least 90 days afterward, with live audio streaming available on SI-BONE’s investor relations website.

.